Compare · ACOR vs GILD
ACOR vs GILD
Side-by-side comparison of Acorda Therapeutics Inc. (ACOR) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACOR and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD carries a market cap of $209.59B.
- GILD has hit the wire 22 times in the past 4 weeks while ACOR has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 0 for ACOR).
- Company
- Acorda Therapeutics Inc.
- Gilead Sciences Inc.
- Price
- -
- $168.98-0.75%
- Market cap
- -
- $209.59B
- 1M return
- -
- +7.95%
- 1Y return
- -
- +32.86%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2006
- 1992
- News (4w)
- 0
- 22
- Recent ratings
- 0
- 25
Acorda Therapeutics Inc.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest ACOR
- Flow Sciences Appoints Michael Gesser as Chief Financial Officer
- SEC Form 10-Q filed by Acorda Therapeutics Inc.
- SEC Form 10-K/A filed by Acorda Therapeutics Inc. (Amendment)
- Acorda Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Acorda Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Acorda Therapeutics Reports Delisting From Nasdaq
- Acorda Therapeutics Announces Delisting from Nasdaq
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
Latest GILD
- Chief Comm & Corp Aff Officer Johanna Mercier exercised 25,000 shares at a strike of $72.34 and sold $4,775,527 worth of shares (28,000 units at $170.55) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 110,684 units (SEC Form 4)
- Chief Financial Officer Andrew D Dickinson sold $514,410 worth of shares (3,000 units at $171.47) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 158,096 units (SEC Form 4)
- Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
- Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
- Director Kramer Kelly A. exercised 10,376 shares at a strike of $66.92 and sold $1,761,437 worth of shares (10,376 units at $169.76) as part of a pre-agreed trading plan (SEC Form 4)
- A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M sold $557,810 worth of shares (3,399 units at $164.11) as part of a pre-agreed trading plan, decreasing direct ownership by 39% to 5,360 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- Chairman & CEO O'Day Daniel Patrick exercised 112,429 shares at a strike of $72.34 and sold $19,693,439 worth of shares (112,429 units at $175.16) as part of a pre-agreed trading plan (SEC Form 4)
- New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention